Sugi Predict

Sugi Predict / Compounds / Ulifloxacin

Ulifloxacin

Ulifloxacin

SCHEMBL1148819

C[C@@H]1Sc2c(C(=O)O)c(=O)c3cc(F)c(N4CCNCC4)cc3n21

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 6/20 0.64
▸ PIM1 P11309 2/20 0.54
▸ GSK3A P49840 2/20 0.54
▸ GSK3B P49841 2/20 0.54
▸ PIM3 Q86V86 2/20 0.54
▸ PRKD3 O94806 1/20 0.54
▸ IRAK1 P51617 1/20 0.54
▸ RPS6KA3 P51812 1/20 0.54
▸ DYRK1A Q13627 1/20 0.54
▸ CSNK1G3 Q9Y6M4 1/20 0.54
▸ ALDH1A1 P00352 7/20 0.53
▸ KDM4E B2RXH2 6/20 0.53
▸ HSD17B10 Q99714 5/20 0.53
▸ HPGD P15428 5/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ TOP2A P11388 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ TOP2B Q02880 1/20 0.53
▸ BRD4 O60885 1/20 0.53
▸ TSHR P16473 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ulifloxacin SCHEMBL1149364 1.00 LMNA (0.64) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1148757 1.00 LMNA (0.64) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL29360160 1.00 LMNA (0.64) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1148707 0.99 LMNA (0.63) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1149252 0.96 LMNA (0.61) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1149423 0.95 LMNA (0.60) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1149353 0.95 LMNA (0.60) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1148815 0.95 LMNA (0.60) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1149416 0.94 LMNA (0.59) LMNAPIM1GSK3AGSK3BPIM3
Ulifloxacin SCHEMBL1148494 0.94 LMNA (0.59) LMNAPIM1GSK3AGSK3BPIM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2258705-B1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD GUANGZHOU BAIYUNSHAN PHARMACEUTICA FACTORY (CN) 2014-06-18 — — EP claimed
EP-2258705-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND Guangzhou Baiyunshan Pharmaceutical Co. Ltd. Guangzhou Baiyunshan Pharmaceutica Factory (CN) 2010-12-08 — — EP claimed
EP-2258705-B1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD GUANGZHOU BAIYUNSHAN PHARMACEUTICA FACTORY (CN) 2014-06-18 — — EP disclosed
EP-2258705-B1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND GUANGZHOU BAIYUNSHAN PHARMACEUTICAL CO LTD GUANGZHOU BAIYUNSHAN PHARMACEUTICA FACTORY (CN) 2014-06-18 — — EP disclosed
US-8501741-B2 Optically active compound of prulifloxacin for treating infection and preparation method thereof HAINAN HUALON PHARMACEUTICAL CO., LTD. (CN) 2013-08-06 — — US disclosed
US-8501741-B2 Optically active compound of prulifloxacin for treating infection and preparation method thereof HAINAN HUALON PHARMACEUTICAL CO., LTD. (CN) 2013-08-06 — — US disclosed
US-20120302580-A1 OPTICALLY ACTIVE COMPOUND OF PRULIFLOXACIN FOR TREATING INFECTION AND PREPARATION METHOD THEREOF HAINAH HUALON PHARMACEUTICAL CO., LTD. (CN) 2012-11-29 — — US disclosed
US-20120302580-A1 OPTICALLY ACTIVE COMPOUND OF PRULIFLOXACIN FOR TREATING INFECTION AND PREPARATION METHOD THEREOF HAINAH HUALON PHARMACEUTICAL CO., LTD. (CN) 2012-11-29 — — US disclosed
CN-102283803-A S-(-)-ulifloxacin injection and preparation method thereof — 2011-12-21 — — CN disclosed
US-20110028444-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS GUANGZHOU PHARMACEUTICAL INDUSTRY ACADEME (CN) 2011-02-03 — — US disclosed
US-20110028444-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS GUANGZHOU PHARMACEUTICAL INDUSTRY ACADEME (CN) 2011-02-03 — — US disclosed
US-20110028444-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS GUANGZHOU PHARMACEUTICAL INDUSTRY ACADEME (CN) 2011-02-03 — — US disclosed
US-20110028444-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS GUANGZHOU PHARMACEUTICAL INDUSTRY ACADEME (CN) 2011-02-03 — — US disclosed
EP-2258705-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND Guangzhou Baiyunshan Pharmaceutical Co. Ltd. Guangzhou Baiyunshan Pharmaceutica Factory (CN) 2010-12-08 — — EP disclosed
EP-2258705-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND Guangzhou Baiyunshan Pharmaceutical Co. Ltd. Guangzhou Baiyunshan Pharmaceutica Factory (CN) 2010-12-08 — — EP disclosed
WO-2009121303-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTIVE QUINOLONE COMPOUND 广州白云山制药股份有限公司广州白云山制药总厂 (CN) 2009-10-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028444-A1 PHARMACEUTICALLY ACCEPTABLE SALTS OF ANTI-INFECTION QUINOLONE COMPOUNDS GLS, ATP6V1B1, CUTA LMNA 4301/4885PIM1 2139/4885GSK3A 1530/4885
US-20120302580-A1 OPTICALLY ACTIVE COMPOUND OF PRULIFLOXACIN FOR TREATING INFECTION AND PREPARATION METHOD THEREOF CYP2C19, Q6ZSR9, UMPS LMNA 2446/4885PIM1 2052/4885GSK3A 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.